-
Electronic (PDF)
-
Site License
-
Enterprisewide
Sigma-Tau S.p.A. - Product Pipeline Review - H2 2011
Global Markets Direct, October 2011, Pages: 99
Sigma-Tau S.p.A. – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Sigma-Tau S.p.A. - Product Pipeline Review - H2 2011” provides data on the Sigma-Tau S.p.A.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sigma-Tau S.p.A.’s corporate website, SEC filings, investor presentations and featured press releases, both from Sigma-Tau S.p.A. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Sigma-Tau S.p.A. - Brief Sigma-Tau S.p.A. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sigma-Tau S.p.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Sigma-Tau S.p.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Sigma-Tau S.p.A.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Sigma-Tau S.p.A.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Sigma-Tau S.p.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Sigma-Tau S.p.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Sigma-Tau S.p.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Sigma-Tau S.p.A. and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Sigma-Tau S.p.A.; Sigma-Tau S.p.A. - Key Therapeutics; Sigma-Tau S.p.A. - Pipeline Overview and Promising Molecules; Sigma-Tau S.p.A. - News; Sigma-Tau S.p.A. - Latest Updates; Sigma-Tau S.p.A. - Pipeline; Sigma-Tau S.p.A. - Discontinued/Dormant Projects
List of Tables
List of Figures
Sigma-Tau S.p.A. Snapshot
Sigma-Tau S.p.A. Overview
Key Information
Key Facts
Sigma-Tau S.p.A. – Research and Development Overview
Key Therapeutic Areas
Sigma-Tau S.p.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Sigma-Tau S.p.A. – Pipeline Products Glance
Sigma-Tau S.p.A. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Sigma-Tau S.p.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sigma-Tau S.p.A.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Sigma-Tau S.p.A. – Drug Profiles
Adarotene
Product Description
Mechanism of Action
R&D Progress
Chenorm
Product Description
Mechanism of Action
R&D Progress
Cystoran
Product Description
Mechanism of Action
R&D Progress
DN30
Product Description
Mechanism of Action
R&D Progress
IART
Product Description
Mechanism of Action
R&D Progress
Rostafuroxin
Product Description
Mechanism of Action
R&D Progress
ST1936
Product Description
Mechanism of Action
R&D Progress
Teglicar
Product Description
Mechanism of Action
R&D Progress
Sigma-Tau S.p.A. – Pipeline Analysis
Sigma-Tau S.p.A. – Pipeline Products by Therapeutic Class
Sigma-Tau S.p.A. - Pipeline Products By Target
Sigma-Tau S.p.A. – Pipeline Products by Route of Administration
Sigma-Tau S.p.A. – Pipeline Products by Molecule Type
Sigma-Tau S.p.A. – Recent Pipeline Updates
Sigma-Tau S.p.A. – Company Statement
Sigma-Tau S.p.A. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Mar 30, 2006: Sigma-tau Strengthens Agreement With Banca Intesa For Gimatecan
Apr 22, 2008: Sigma-Tau Pharmaceuticals Receives Orphan-Drug Designation For Artesunate For The Immediate Treatment Of Malaria From The European Commission
May 17, 2010: Sigma-Tau's NDA For Cysteamine Hydrochloride Ophthalmic Solution Accepted For Filing By FDA
Jun 13, 2006: The Debiopharm Group And Sigma-Tau Sign R&D And Commercial Agreement For Istaroxime In Acute Heart Failure Syndromes
Apr 07, 2009: Sigma-Tau Partners With Danisco Bioactive To Develop Drug Candidate For Prevention Of Necrotizing Enterocolitis
Nov 06, 2003: Novartis Signs License Agreement To Develop And Globally Commercialize Cancer-Compound Gimatecan From Sigma-Tau
Financial Deals Landscape
Sigma-Tau S.p.A., Deals Summary
Sigma-Tau S.p.A., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Sigma-Tau Acquires Specialty Pharmaceutical Business From Enzon Pharmaceuticals
Sigma-Tau Pharmaceuticals Acquires Chenix From Solvay Pharmaceuticals
Sigma-Tau Pharmaceuticals Acquires Chenofalk
Partnerships
Dyax Expands Its Agreement With Defiante Farmaceutica
Dyax Expands Its Collaboration With Defiante Farmaceutica
Dyax Enters Into Co-Development Agreement With Defiante Farmaceutica
Endotis Pharma Enters Into Co-development Agreement With Tecnogen
Endotis Enters Into Manufacturing And Co-Development Agreement With Tecnogen
Sigma-Tau Pharmaceuticals Signs Partnership Agreement With Danisco Bioactive
Anesiva Expands Its Agreement With Sigma-Tau
Anesiva Entered Into Agreement With Sigma-Tau
Walter Reed Army Institute of Research And U.S. Army Medical Materiel Development Activity Form Partnership With Sigma-Tau Pharmaceuticals
BurnsAdler Pharmaceuticals Enters Into Partnership With Sigma-Tau
BurnsAdler Pharmaceuticals Enters Into Co-Promotion Agreement With Sigma-Tau
Licensing Agreements
Soligenix Expands Licensing Agreement With Sigma-Tau Pharmaceuticals For orBec
Gentium Enters Into Licensing Agreement With Sigma-Tau Pharmaceuticals
DOR BioPharma Enters Into Licensing Agreement With Sigma-Tau Pharmaceuticals For orBec
Pfizer Enters Into Licensing Agreement With Sigma-Tau
ViRexx Medical Enters Into Licensing Agreement With Defiante Farmaceutica
Debiopharm Enters Into Licensing Agreement with Sigma-Tau
BioDelivery Sciences International Enters Into Licensing Agreement With Sigma-Tau
RegeneRx Biopharmaceuticals Enters Into Licensing Agreement With Defiante Farmaceutica
Equity Offering
RegeneRx Biopharmaceuticals Completes Registered Direct Offering Of $1.45 Million
Soligenix Completes Private Placement Of Its Common Stock For $6 Million
RegeneRx Biopharmaceuticals Completes Private Placement Of $1 Million
DOR BioPharma Completes Private Placement Of $4.39 Million
Soligenix Completes Private Placement Of $4.5 Million
DOR BioPharma Completes Private Placement Of $1.5 Million
RegeneRx Biopharmaceuticals Completes Private Placement Of $5 Million
DOR BioPharma Completes Private Placement Of $1 Million
RegeneRx Completes Private Placement Of $9.55 Million
RegeneRx Biopharmaceuticals Completes Registered Direct Offering For $7.3 Million
RegeneRx Raises $1.5 Million Upon Exercise Of Warrants
RegeneRx Biopharmaceuticals Completes Private Placement Of $2.3 Million
Acquisition
Banca Intesa Acquires 5% Stake In Sigma-Tau
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Sigma-Tau S.p.A. – Pipeline by Therapy Area and Indication, H2 2011
Sigma-Tau S.p.A. – Pipeline by Stage of Development, H2 2011
Sigma-Tau S.p.A. – Monotherapy Products in Pipeline, H2 2011
Sigma-Tau S.p.A. – Filed, H2 2011
Sigma-Tau S.p.A. - Phase II, H2 2011
Sigma-Tau S.p.A. - Phase I, H2 2011
Sigma-Tau S.p.A. - Pipeline By Therapeutic Class, H2 2011
Sigma-Tau S.p.A. - Pipeline By Target, H2 2011
Sigma-Tau S.p.A. – Pipeline By Route of Administration, H2 2011
Sigma-Tau S.p.A. – Pipeline By Molecule Type, H2 2011
Sigma-Tau S.p.A. – Recent Pipeline Updates, H2 2011
Sigma-Tau S.p.A., Subsidiaries
Sigma-Tau S.p.A., Deals Summary
Sigma-Tau Acquires Specialty Pharmaceutical Business From Enzon Pharmaceuticals
Sigma-Tau Pharmaceuticals Acquires Chenix From Solvay Pharmaceuticals
Sigma-Tau Pharmaceuticals Acquires Chenofalk
Dyax Expands Its Agreement With Defiante Farmaceutica
Dyax Expands Its Collaboration With Defiante Farmaceutica
Dyax Enters Into Co-Development Agreement With Defiante Farmaceutica
Endotis Pharma Enters Into Co-development Agreement With Tecnogen
Endotis Enters Into Manufacturing And Co-Development Agreement With Tecnogen
Sigma-Tau Pharmaceuticals Signs Partnership Agreement With Danisco Bioactive
Anesiva Expands Its Agreement With Sigma-Tau
Anesiva Entered Into Agreement With Sigma-Tau
Walter Reed Army Institute of Research And U.S. Army Medical Materiel Development Activity Form Partnership With Sigma-Tau Pharmaceuticals
BurnsAdler Pharmaceuticals Enters Into Partnership With Sigma-Tau
BurnsAdler Pharmaceuticals Enters Into Co-Promotion Agreement With Sigma-Tau
Soligenix Expands Licensing Agreement With Sigma-Tau Pharmaceuticals For orBec
Gentium Enters Into Licensing Agreement With Sigma-Tau Pharmaceuticals
DOR BioPharma Enters Into Licensing Agreement With Sigma-Tau Pharmaceuticals For orBec
Pfizer Enters Into Licensing Agreement With Sigma-Tau
ViRexx Medical Enters Into Licensing Agreement With Defiante Farmaceutica
Debiopharm Enters Into Licensing Agreement with Sigma-Tau
BioDelivery Sciences International Enters Into Licensing Agreement With Sigma-Tau
RegeneRx Biopharmaceuticals Enters Into Licensing Agreement With Defiante Farmaceutica
RegeneRx Biopharmaceuticals Completes Registered Direct Offering Of $1.45 Million
Soligenix Completes Private Placement Of Its Common Stock For $6 Million
RegeneRx Biopharmaceuticals Completes Private Placement Of $1 Million
DOR BioPharma Completes Private Placement Of $4.39 Million
Soligenix Completes Private Placement Of $4.5 Million
DOR BioPharma Completes Private Placement Of $1.5 Million
RegeneRx Biopharmaceuticals Completes Private Placement Of $5 Million
DOR BioPharma Completes Private Placement Of $1 Million
RegeneRx Completes Private Placement Of $9.55 Million
RegeneRx Biopharmaceuticals Completes Registered Direct Offering For $7.3 Million
RegeneRx Raises $1.5 Million Upon Exercise Of Warrants
RegeneRx Biopharmaceuticals Completes Private Placement Of $2.3 Million
Banca Intesa Acquires 5% Stake In Sigma-Tau
List of Figures
Sigma-Tau S.p.A. – Pipeline by Therapy Area and Indication, H2 2011
Sigma-Tau S.p.A. – Pipeline by Stage of Development, H2 2011
Sigma-Tau S.p.A. – Monotherapy Products in Pipeline, H2 2011
Sigma-Tau S.p.A. – Pipeline By Therapeutic Class, H2 2011
Sigma-Tau S.p.A. - Pipeline By Target, H2 2011
Sigma-Tau S.p.A. – Pipeline By Route of Administration, H2 2011
Sigma-Tau S.p.A. – Pipeline By Molecule Type, H2 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
